High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis

Koji Ishikawa¹,²,³, Takashi Nagai¹, Koki Tsuchiya¹, Yusuke Oshita³, Takuma Kuroda¹, Hiroshi Ito¹, Soji Tani¹, Yusuke Dodo¹, Tomoaki Toyone¹, Katsunori Inagaki¹

¹Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan; ²Department of Orthopaedic and Spine Surgery, Sanraku Hospital, Tokyo, Japan; ³Department of Orthopaedic Surgery, Yamanashi Red Cross Hospital, Yamanashi, Japan

Correspondence: Koji Ishikawa
Department of Orthopaedic Surgery, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
Tel +81 3 3784 8543
Fax +81 3 3784 9005
Email koji.ishikawa@med.showa-u.ac.jp

Abstract: Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL) that is used for the treatment of osteoporosis. Denosumab-induced hypocalcemia is a rare but important adverse event, which is usually asymptomatic in patients with osteoporosis. It is also known that hypocalcemia is common in patients with bone metastases and severe renal impairment. Here we report a case of symptomatic hypocalcemia following administration of 60 mg of denosumab in a patient with high bone turnover and no renal impairment (estimated glomerular filtration rate [eGFR], 71 mL/min), despite prophylactic oral vitamin D administration. This report supports our observation that there is a risk of protracted and marked denosumab-induced hypocalcemia in patients with high bone turnover, irrespective of their degree of renal impairment.

Keywords: denosumab, symptomatic hypocalcemia, high bone turnover, no renal impairment

Introduction
Osteoporosis is recognized as one of the most common public health problems, especially in the elderly population.¹ There are many medications available to manage osteoporosis. Denosumab is a novel agent that is approved for the treatment of osteoporosis and for the prevention of skeletal-related events in patients with bone metastases. In men and postmenopausal women with osteoporosis, a single 60 mg dose of denosumab administered subcutaneously every 6 months significantly reduces bone turnover markers, increases bone mineral density (BMD), and reduces the risk of new fractures.² Denosumab is not associated with delayed healing or other complications following fractures.³ However, it is associated with several serious adverse effects, including hypocalcemia.⁴⁻¹² Hypocalcemia is a rare adverse event associated with denosumab and may present with serious manifestations, including cardiac arrhythmia and death.¹¹⁻¹⁴ In general, most incidents of hypocalcemia are asymptomatic, especially in patients with osteoporosis.¹⁵,¹⁶ Hypocalcemia is most common with the use of denosumab for the prevention of skeletal-related events in patients with bone metastases.¹⁷ The generally recognized risk factors for hypocalcemia are renal impairment and lack of prophylactic administration of calcium and activated vitamin D. We recently reported that high bone turnover was also associated with a higher risk of denosumab-induced hypocalcemia in patients with postmenopausal osteoporosis.¹⁶ However, all cases of hypocalcemia in that series were asymptomatic. Here, we present the case of a male patient with symptomatic hypocalcemia and high bone turnover status induced by a single, 60 mg dose of denosumab, even though...
he was receiving prophylactic vitamin D and had normal renal function.

**Case presentation**

A 68-year-old man presented to our hospital with a 1-week duration of back pain that appeared after he lifted a heavy object while cleaning his house. He underwent an apparently curative laparoscopic distal gastrectomy for gastric cancer 2 years ago. There was no evidence of residual cancer following his operation, and he did not receive any adjuvant treatment in the past year. He was not on any medications for other diseases, including osteoporosis. Plain lateral radiographs of the spine and MRI demonstrated a fresh vertebral fracture at L3 and T12 (Figure 1). Bone metastases were not identified through medical examination. He was treated conservatively, using a rigid brace to stabilize his spine. He also received a single, 60 mg dose of denosumab subcutaneously, and was started on a prophylactic dose of oral eldecalcitol (0.75 µg/d) for osteoporosis (DXA [Dual energy X-ray absorptiometry]: spine BMD, 0.594 mg/cm²; femoral neck BMD, 0.445 mg/cm²). Prior to the administration of denosumab, the results of his laboratory investigations were as follows: serum corrected calcium, 8.8 mg/dL (reference range [RR], 8.7–10.2 mg/dL); phosphorus, 3.4 mg/dL (RR, 2.5–4.5 mg/dL); magnesium, 2.1 mg/dL (RR, 1.7–2.6 mg/dL), alkaline phosphatase, 308 U/L (RR, 104–338 U/L); serum creatinine, 0.83 mg/dL (RR, 0.65–1.09 mg/dL), estimated glomerular filtration rate (eGFR), 71 mL/min (RR, ≥60 mL/min), eGFR level was calculated using the formula developed by the Japanese Society of Nephrology;¹⁸ and 1,25-dihydroxyvitamin D (1,25(OH)₂D), 43 pg/mL (RR, 20–60 pg/mL). Further, he was found to have secondary hyperparathyroidism (intact parathyroid hormone [intact PTH], 148 pg/mL [RR, 10–65 pg/mL]; vitamin D deficiency (1,25(OH)₂D), 6.6 ng/mL [RR, 20–100 ng/mL]) and high bone turnover status (total N-terminal propeptide of type 1 procollagen [total P1NP], 94.9 µg/L [RR, 18.1–74.1 µg/L]; tartrate-resistant acid phosphatase type 5 [TRACP-5b], 900 mU/dL [RR, 170–590 mU/dL]). The patient was due for the next blood test after 14 days.

The patient developed nausea, vomiting, decreased appetite, and paresthesia in the extremities and around the mouth 14 days following denosumab administration. Blood tests identified grade 3 hypocalcemia (corrected calcium, 6.9 mg/dL) according to the National Cancer Institute’s Common Toxicity Criteria for Adverse Events version 4.0. He was found to have phosphate serum levels of 2.9 mg/dL and intact PTH of 744 pg/mL. Electrocardiogram demonstrated normal sinus rhythm without QT prolongation. After a discussion of the risks and benefits, the patient consented to careful calcium homeostasis management as an outpatient. He was supplemented with 3,000 mg/dL of oral calcium along with a prophylactic dose (0.75 µg/dL) of oral eldecalcitol, which resolved his symptoms. His serum calcium normalized (corrected calcium, 8.7 mg/dL) 21 days post denosumab. Subsequently, he was managed on an outpatient basis with close monitoring of calcium homeostasis and bone turnover markers. The patient received three more courses of denosumab, during which he maintained his calcium levels with oral calcium (3,000–4,000 mg/dL) and vitamin D supplementation (Figure 2). During denosumab treatment, there was an immediate reduction in bone turnover markers (Figure 3) and a successful increase in the BMD (DXA: spine BMD, from 0.594 to 0.893 mg/cm²; femoral neck BMD, from 0.445 to 0.456 mg/cm²). There was a mild deterioration in renal function during the course of his treatment (Figure 3). 1,25(OH)₂D was suppressed, while 25(OH)D increased in summer and autumn and decreased in winter (Figure 4).

**Consent**

Written informed consent was obtained from the patient for the publication of this case report.
High bone turnover in denosumab-induced symptomatic hypocalcemia

Discussion

In a major clinical trial, there were no reports of hypocalcemia (serum calcium <8.0 mg/dL) among 3,886 women who received denosumab over a 3-year follow-up. However, previous case reports suggested a variable incidence of denosumab-induced symptomatic hypocalcemia in patients with osteoporosis, the majority of whom had renal failure. Consequently, current recommendations suggest monitoring calcium levels in patients with reduced renal function. Our patient developed symptomatic hypocalcemia following denosumab administration, in the absence of any renal impairment. Although they do not provide the cause of the hypocalcemia, recent case reports suggest that calcium level monitoring may be necessary for any degree of renal failure. These levels may be monitored 1–2 weeks following the administration of denosumab, to correspond to the nadir of its action. In the current case report, it is possible that life-threatening hypocalcemia was mitigated by its early detection on routine monitoring and timely extra oral calcium supplementation.

Figure 2 Serum calcium and intact PTH levels.
Notes: After the serum calcium was normalized, it did not change significantly over the three courses of denosumab. PTH continued to be elevated 2 weeks following denosumab administration. Subsequently, PTH was normalized owing to calcium supplementation.
Abbreviations: M, month; Ca, calcium; PTH, parathyroid hormone.

Figure 3 Bone turnover markers (TRACP-5b, total-P1NP) and eGFR levels.
Notes: TRACP-5b and total-P1NP levels decreased immediately following the first course of denosumab treatment. Renal function diminished mildly over the entire course of treatment.
Abbreviations: M, month; TRACP-5b, tartrate-resistant acid phosphatase type 5; total-P1NP, total N-terminal propeptide of type 1 procollagen; eGFR, estimated glomerular filtration rate.
In general, the risk factors for hypocalcemia include renal impairment, vitamin D deficiency, and lack of prophylactic supplementation.\(^\text{12,15}\) However, increasing attention has been paid to high bone turnover as a risk factor for denosumab-induced hypocalcemia.\(^\text{11,16,19}\) Among these risk factors, our patient had high bone turnover and vitamin D deficiency in the present case. Symptomatic hypocalcemia occurred only once, at 2 weeks following the initial administration, throughout the three courses of denosumab. Interestingly, levels of 25(OH)D remained relatively unaltered during the treatment, and renal function appeared to gradually deteriorate. One factor that changed dramatically was bone turnover (total P1NP: from 94.9 to 41.8 µg/L [from baseline to 2 weeks], TRACP-5b: from 900 to 347 mU/dL), and that change was most significant following the first course of denosumab at almost exactly the same time as the patient exhibited symptomatic hypocalcemia. Therefore, it is our opinion that high bone turnover may be the principal predisposing factor for symptomatic hypocalcemia in our patient, and not vitamin D deficiency. We have previously demonstrated that denosumab administration has a greater impact on serum calcium levels in patients with high bone turnover as maintaining normocalcemia in this group is more dependent on bone resorption.\(^\text{16}\) Following our article, one recent study investigated calcium levels after administration of denosumab after switching from teriparatide therapies to denosumab showed a significant decrease compared with the other groups, meaning that high bone turnover is potentially a risk factor in denosumab-induced hypocalcemia. In particular, they also found that there were no significant correlations between serum 25(OH)D level at baseline and changes in serum calcium level. The majority of patients in a number of studies, including the patient in the present case, developed hypocalcemia after the first dose of denosumab.\(^\text{5,7–12,19}\) In fact, there were no differences in serum calcium level from the second dose of denosumab to 1 week later.\(^\text{19}\) This may be explained by low bone turnover in the majority of patients after the first course of denosumab. Therefore, the risk of hypocalcemia is reduced after the second and subsequent doses of denosumab, as seen in the present case.

The high baseline PTH in the presence of normocalcemia suggests that serum calcium is maintained by the PTH-mediated mobilization of calcium from skeletal stores and by stimulation of bone resorption. It is generally agreed that secondary hyperparathyroidism is associated with a high bone turnover status, implying that patients with secondary hyperparathyroidism are at an increased risk for denosumab-induced hypocalcemia. Elevated PTH following denosumab administration contributes to serum calcium maintenance, and the lack of this elevation may result in inadequate mobilization of bone calcium, and therefore severe hypocalcemia. To the best of our knowledge, this is the first report to measure the PTH levels over the treatment period and

\[\text{Figure 4} \quad 1,25(\text{OH})_2\text{D and 25(OH)D levels.}
\]

**Notes:** 1,25(\text{OH})_2\text{D} was suppressed following eldecalcitol supplementation. 25(OH)D level is higher in summer and autumn and lower in winter.

**Abbreviations:** M, month; 1,25(\text{OH})_2\text{D}, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin.
showed a transient acute increase in PTH levels following denosumab administration with a concomitant decrease in serum calcium levels.

Moreover, it is important for vitamin D deficiency to be corrected, if possible, prior to denosumab administration. 1,25(OH)₂D stimulates calcium absorption in the intestines and bone mineralization, and its deficiency has a strong bearing on serum calcium levels. In our case, 1,25(OH)₂D was suppressed by about 33.8% throughout the treatment course with eldecalcitol, which is consistent with the observation of a previous study that investigated the time course of change after eldecalcitol supplementation. 20 25(OH)D was not altered significantly, and the observed changes corresponded to the expected seasonal variations in its concentration, as its levels are primarily dependent on climate and sun exposure. 21

Our patient had a history of laparoscopic distal gastrectomy. A previous study reported that gastrectomy did not increase the risk of developing denosumab-induced hypocalcemia in patients with gastric cancer and bone metastases. 22 However, gastrectomy is a known risk factor for osteoporosis. 23 After gastrectomy, reduced gastric acid secretion impairs calcium ionization and, in the setting of calcium and vitamin D deficiency, may also cause hypocalcemia.

We are unable to fully explain the pathophysiology of hypocalcemia in our case. However, since the only instance in which hypocalcemia occurred following the first course of denosumab, we hypothesized that it was precipitated by the disruption of the high bone turnover state by denosumab. Furthermore, our case showed that elevated PTH levels following denosumab administration may play an important role in the normalization of calcium levels. Thus, on the basis of our experience, including the previous study, we recommend that a thorough evaluation, including bone turnover markers, renal function, PTH and 25(OH)D levels, is essential in patients slated for denosumab therapy. 16 Moreover, close monitoring of serum calcium following the first course of denosumab is necessary in patients with high bone turnover, irrespective of their degree of renal failure.

Our case report has some limitations. First, our patient presented to our hospital 1 week after he sustained a vertebral fracture, which may have increased the levels of the bone turnover marker. However, since bone turnover markers usually peak several weeks following most fractures, this is a remote possibility. Second, although our hypothesis is based on the previous article 11,16,19 we experienced symptomatic hypocalcemia in only one case.

In conclusion, this is the first case report of denosumab-induced symptomatic hypocalcemia in a patient with osteoporosis and absence of renal impairment that clearly documents the role of high bone turnover state as a risk factor. Appropriate preassessment of bone and calcium homeostasis, including bone turnover status, may help in identifying patients at a higher risk for denosumab-induced hypocalcemia. With proactive and careful monitoring, denosumab-induced hypocalcemia can be prevented and managed effectively in patients with osteoporosis. Clinicians should at least consider the possibility of a higher risk of denosumab-induced hypocalcemia in the presence of high bone turnover and identify potentially high-risk patients for early intervention.

Acknowledgment

The authors thank Ayano Oyamada, Tatsuyo Shinhohara, Mayumi Otsu, Rikako Ono, Yoko Matsumoto, Takeshi Eguro, Keizo Sakamoto, Shigeo Sano, and Yusuke Nakao for their cooperation with osteoporosis treatment and technical assistance.

Disclosure

The authors report no conflicts of interest in this work.

References

1. McCurry J. Japan will be model for future super-ageing societies. Lancet. 2015;386(10003):1523.